Business
Human hand and AI hand on the yellow background
Getty Images
PEAK CONSULTING?

After three decades of pretty constant growth, the consultancy boom just hit an AI-shaped wall

Accenture has a new deal with OpenAI — did ChatGPT’s launch top-tick consulting employment?

Hyunsoo Rim

The age of consulting as we know it, when armies of associates mercilessly grind through endless slide decks and dashboards, is starting to give way to a new model: part human, part bot.

On Monday, Accenture announced a new partnership with OpenAI to roll out ChatGPT Enterprise for “tens of thousands of its professionals,” embedding the tool across consulting, operations, and delivery work. The company also said it will now have the “largest number of professionals upskilled through OpenAI Certifications.”

The collaboration follows Accenture’s $865 million restructuring plan unveiled in September, in which the company euphemistically disclosed that it’s been “exiting” employees who cannot be re-skilled for AI.

Peak consulting?

The partnership is good news for consultants looking to decorate their LinkedIn profiles with AI badges, but it also reflects a deep shift within the industry, as the traditional model built on adding more people to bill for long hours begins to unwind.

Consulting's 30-Year Climb Just Hit A Wall
Sherwood News

According to Bureau of Labor Statistics data, consulting’s share of total US employment has grown more than 4x since 1990, though it stopped rising around late 2022 — just as generative AI took off on the back of ChatGPT’s debut. The industry’s stall appears more pronounced than other white-collar jobs that hit their plateaus much earlier, from the dot-com crash in tech to the post-2008 slowdown in Wall Street, which have all recently been impacted by the AI boom in quite different ways.

And things could get even worse for the consulting industry before they get better. A new study from HFS Research and IBM found that nearly two-thirds (65%) of enterprise executives say traditional consulting models no longer deliver real value, while 83% say AI-powered consulting delivers more.

More Business

See all Business
business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.